Get started
Author

Laetitia Petersen

Observed name: L PETERSEN
Observed institution: F. Hoffmann-La Roche AG
OpenAlex ID: A5111575974
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
2008 · Maria Amann, Klaus Brischwein, et al. · Cancer Research · 88
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
2008 · Maria Amann, Matthias Friedrich, et al. · Cancer Immunology Immunotherapy · 40
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
2006 · E KRINNER, T RAUM, et al. · Molecular Immunology · 31
Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model
2006 · Petra Lutterbuese, Klaus Brischwein, et al. · Cancer Immunology Immunotherapy · 15
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
2024 · Patrizia Murer, Barbara Brannetti, et al. · mAbs · 14
PDF
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice
2022 · Jerome Egli, Stefan Heiler, et al. · mAbs · 12
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy
2025 · Patrizia Murer, Laetitia Petersen, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
820 ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors
2023 · Patrizia Murer, Ulisse Salazar, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
954 ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes
2024 · Patrizia Murer, Anais Zurbach, et al. · Journal for ImmunoTherapy of Cancer
960 ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells
2024 · Alexander Rau, Nicole Egli, et al. · Journal for ImmunoTherapy of Cancer
Abstract 4127: ANV600 is a potent, Cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells
2023 · Patrizia Murer, Ulisse Salazar, et al. · Cancer Research
1099 ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein showing increased efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity
2022 · Christoph Huber, Kirsten Richter, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 12
Citation count: 212
H-index: 7
I10-index: 7
Year
Topic
Type